MedTrace Logo

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

NCT03650257 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-03-12

No results posted yet for this study

Summary

This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.

Conditions

  • Glioma of Brain

Interventions

BIOLOGICAL

gp96

25 mcg IH

DRUG

Temozolomide

temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).

RADIATION

radiotherapy

Stupp regimen of radiotherapy

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Shenzhen Second People's Hospital

    collaborator OTHER

  • Cure&Sure Biotech Co., LTD

    lead INDUSTRY

Principal Investigators

  • zhixian Gao, Doctor · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-21
Primary Completion
2021-08-20
Completion
2024-08-20
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03650257 on ClinicalTrials.gov